Overview
Urteste is developing the world's first method for detecting multiple cancers from a single urine sample. This early cancer detection technology aims to enable effective treatment by identifying the disease at an early stage.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 42.90
- High
- PLN 42.90
- Low
- PLN 41.90
- Volume
- 32
- Avg. vol.
- 1.18K
- Market cap
- PLN 63.94M
- P/E ratio
- –
- EPS
- -PLN 2.37
- Shares outstanding
- 1.53M
- 52-week
- PLN 40.20 – 43.50
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLURTST00010
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 810.37 | USD 501.62k | USD 489.20k |
| Q1 2026 | – | USD -488.11k | USD -501.62k |
| Q4 2025 | – | USD -461.07k | USD -473.88k |
| Q3 2025 | – | USD -421.15k | USD -422.15k |
Results for Q3 2026:Nov 30, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2019-06-08. Active
25 1050 1764 1000 0090 8196 6336- 44 1050 1764 1000 0090 8061 8276
- 66 1050 1764 1000 0090 8061 8268
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 29, 2021 | Transformation registered |
Public aid
11 public aid cases recorded, with a total value of $14,588,265.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 21, 2024 | Aid for research and development projects: experimental development | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Nov 21, 2024 | Aid for research and development projects: industrial research | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Nov 21, 2024 | Aid for SMEs for innovation support | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $14,580,706.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-01-02 | Test NASTRO – bazujący na metodzie enzymatycznej, nisko kosztowy test IVD do diagnozowania raka piersi we wczesnych stadiach rozwoju oraz międzynarodowa ochrona praw własności przemysłowej nowego markera diagnostycznego piersi a także zdobywanie i rozwój kompetencji Zespołu URTESTE S.A. w obszarze prac B+R i ich komercjalizacji. | $2.9M$2,873,572 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2023-05-10 | Test PANURI – bazujący na metodzie enzymatycznej, wysoko skuteczny i nisko kosztowy test IVD do diagnozowania raka trzustki we wczesnych stadiach rozwoju oraz międzynarodowa ochrona praw własności przemysłowej wynalazków w postaci testów IVD do oznaczania innych nowotworów bazujących na metodzie enzymatycznej. | $9.1M$9,103,773 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2023-05-01 | Test diagnostyczny do wykrywania nowotworu trzustki we wczesnym stadium jego rozwoju. | $2.6M$2,586,802 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
No recorded participation in tenders.
Trademarks
Urteste holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2021.
| Mark | Protected until | |
|---|---|---|
| URTESTE(word) | Jan 22, 2031 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board as well as a multi-member management board, each member of the management board is authorised to make declarations within the scope of the company’s rights and obligations independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| IntodnaS.A. | $2,286,118.76 | intodna.com | ||
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| MolecureS.A. | $2,015,601.71 | molecure.com | ||
| GMT GenomicsS.A. | $89,076.86 | genomtec.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-07 | Share capital change (140,966.90 PLN → 152,608.00 PLN) | |
| 2023-06-07 | Share capital change (114,028.00 PLN → 140,966.90 PLN) | |
| 2022-04-01 | Share capital change (111,978.80 PLN → 114,028.00 PLN) | |
| 2021-08-12 | Share capital change (102,458.80 PLN → 111,978.80 PLN) | |
| 2021-05-10 | Share capital change (100,000.00 PLN → 102,458.80 PLN) |
FAQ
Last updated: 2026-10-07